Most Immunosuppressive Drugs Not Linked to Risk for Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 28, 2023 -- For patients with ocular inflammatory disease (OID), short-term therapy with commonly used immunosuppressive drug classes and many drugs is not associated with an increased risk for cancer incidence, according to a study published online Aug. 21 in BMJ Oncology.
Jeanine M. Buchanich, Ph.D., from the University of Pittsburgh School of Public Health, and colleagues conducted a retrospective cohort study involving patients from 10 U.S. OID subspecialty practices. Time-dependent exposure to drug classes and drugs was evaluated. By linkage to 12 state cancer registries, cancer incidence was ascertained.
The cancer incidence cohort included 10,872 individuals at risk for incident cancer and residing in one of the 12 states covered. With median follow-up of 10 years, the researchers identified 812 primary cancers. After adjustment for covariates, there were no associations for tumor necrosis factor inhibitor, antimetabolite, calcineurin inhibitor, or alkylating agent classes with significant increases in cancer. In the systemic inflammatory disease (SID)-including cohort, significantly reduced hazards were seen for adalimumab and chlorambucil, while increased hazards were seen for tacrolimus and etanercept in the non-SID cohort; in both, reduced hazards were seen for methotrexate. No association with overall cancer incidence was seen for other immunosuppressive drugs.
"Immunosuppressants are widely used and transformative for care of patients with inflammatory diseases, but the potential concern that they carry a cancer risk has forced people to make difficult decisions without enough information. Alleviating that concern with use for inflammatory diseases will help people make the treatment decision that's right for them," Buchanich said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Recommendations Issued for Palliative RT for Symptomatic Bone Mets
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...
Living Outside of Comprehensive Cancer Center Catchment Area Tied to Later-Stage Diagnosis
TUESDAY, May 28, 2024 -- Disadvantaged populations and those living outside of a comprehensive cancer center's main catchment area have higher odds of receiving a diagnosis of...
Disparities Seen in Cancer Treatment Delivery at Minority-Serving Hospitals
TUESDAY, May 28, 2024 -- There are systemic disparities in definitive cancer treatment delivery at minority-serving hospitals (MSHs) versus non-MSHs, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.